CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

November 16, 2020

Study Completion Date

November 16, 2020

Conditions
CancerNon Small Cell Lung Cancer MetastaticMetastatic MelanomaNeoplasm of LungMelanoma
Interventions
DRUG

APX005M

APX005M is a CD40 agonistic monoclonal antibody

DRUG

Nivolumab

Nivolumab is an immune checkpoint (PD-1) blocking antibody

Trial Locations (23)

13210

SUNY Upstate Medical Hospital, Syracuse

19046

Fox Chase Center, Rockledge

19104

Abramson Cancer Center of The University of Pennsylvania, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

21201

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore

27003

H. Lucus Augusti, Lugo

28041

H. Doce de Octubre, Madrid

28050

H. HM Sanchinnarro, Madrid

29010

H. de Málaga, Málaga

32952

Hem-Onc Associates of the Treasure Coast, Port Saint Lucie

37203

Tennessee Oncology, Nashville

44106

University Hospitals Seidman Cancer Center, Cleveland

46014

H. La Fe, Valencia

H. General de Valencia, Valencia de Alcántara

68130

Nebraska Cancer Specialists, Omaha

68198

University of Nebraska Medical Center, Omaha

85724

University of Arizona Cancer Center, Tucson

91010

City of Hope, Duarte

06520

Yale University, New Haven

08028

Hospital Quirón Dexeus, Barcelona

08035

H. Vall d'Hebron, Barcelona

08036

H. Clinic i Provincial, Barcelona

Unknown

H. Insular de Gran Canaria, Las Palmas de Gran Canaria

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Apexigen America, Inc.

INDUSTRY